Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Feb 14, 2017
Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook
Achieved Profit in the Fourth Quarter of 2016; Guides to Full Year Profit in 2017
Delivered 14 Percent Revenue Growth and 11 Percent Test Growth in 2016
Generated $3.6M Prostate Revenue and Increased Prostate Test Volume by 29 Percent in the Fourth Quarter
Conference Call Today at 4:30 p.m. ET
Feb 07, 2017
Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017
REDWOOD CITY, Calif. , Feb. 7, 2017 /PRNewswire/ --  Genomic Health, Inc.  (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 14 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2016 financial results.  The call and
Jan 03, 2017
Genomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Jan. 3, 2017 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the 35 th Annual J.P. Morgan Healthcare Conference at the Westin St.
Dec 22, 2016
Genomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging
For the First Time, AJCC Adds Molecular Markers to Staging Criteria, Including Oncotype DX along with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 Status
Dec 09, 2016
Genomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World
Presentations at 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) Highlight Unique Value of Oncotype DX in Tailoring Treatment Across the Breast Cancer Patient Journey
Nov 29, 2016
Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine
REDWOOD CITY, Calif. , Nov. 29, 2016 /PRNewswire/ --  Genomic Health, Inc. ( NASDAQ : GHDX) today announced that it will present seven Oncotype DX ® studies at the 39 th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016 .
Nov 03, 2016
Genomic Health to Present at the Credit Suisse 25th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole , chief operating officer and chief financial officer, will present at the Credit Suisse 25 th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 8, 2016 at
Nov 01, 2016
Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results
12% Increase in Revenue; 8% Increase in Tests Delivered
18% Constant Currency Increase in International Revenue and 15% Growth in International Tests Delivered
45% Improvement in Year-to-Date Operating Loss
Oncotype DX® Genomic Prostate Score™ Now Validated as Only Test to Measure All Four Critical Features of Tumor Aggressiveness
Conference Call Today at 4:30 p.m. ET
Nov 01, 2016
Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk of Metastasis and Mortality
Oncotype DX® Genomic Prostate Score™ Becomes Only Test Validated to Measure All Four Critical Features of Tumor Aggressiveness
Oct 26, 2016
Comprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance
Unique Prospective Study Provides Real-world Evidence Demonstrating Use of Oncotype DX® Genomic Prostate Score™ Saves Over $2,000 per Patient by Optimizing Care and Healthcare Spending